Literature DB >> 26386087

Tumor Marker Ordering: Do Not Lose Control: A Prospective Clinical Trial.

Simona Ferraro1, Roberta Mozzi2, Mauro Panteghini2.   

Abstract

OBJECTIVES: In this study, we evaluated the extent of inappropriate tumor marker (TM) ordering in a secondary care setting, approximately 6 years after the introduction of local guidelines, and we identified the main factors potentially influencing clinicians when performing an inappropriate TM request.
METHODS: For this purpose, we regularly checked all requests containing more than two TMs. During the 21-month audit, the rate of rejected requests amounted to 3.6%. Several of those were performed for diagnostic purposes. The most frequent and inappropriately requested TMs were carcinoembryonic antigen and carbohydrate antigen 19.9.
RESULTS: The inappropriateness of requests appeared to be linked to the need for more education and knowledge on their clinical applicability and limitations. The clinical motivation was generally associated with patients displaying nonspecific signs/symptoms (ie, weight loss with worsening general conditions), having an incidentally positive result to some recently performed TM tests, or being tested by a TM to avoid more expensive diagnostic imaging procedures.
CONCLUSIONS: Our data show that real-time control and management of inappropriate requests by laboratory professionals may be relevant to increase the clinical efficacy of TM testing and useful in perspective to drive the introduction of new validated biomarkers. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Appropriateness; Diagnosis; Efficacy; Test request; Tumor markers

Mesh:

Substances:

Year:  2015        PMID: 26386087     DOI: 10.1309/AJCPNZAPJRB3T6KK

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  A preliminary assessment of oral monepantel's tolerability and pharmacokinetics in individuals with treatment-refractory solid tumors.

Authors:  Anna Mislang; Richard Mollard; Gonzalo Tapia Rico; W Douglas Fairlie; Erinna F Lee; Tiffany J Harris; Roger Aston; Michael P Brown
Journal:  Cancer Chemother Pharmacol       Date:  2020-09-22       Impact factor: 3.333

2.  TAP Test Image Dynamic Tracking Study after Thyroid Cancer Surgery and after Radiotherapy and Chemotherapy.

Authors:  Changliang Wang; Yongxue Gu; Xiaojuan Men; Peng Sun; Meili Chen
Journal:  Comput Math Methods Med       Date:  2021-04-16       Impact factor: 2.238

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.